SB
Sarai Bronfeld
Partner at NFX
Tel Aviv-Yafo, Tel Aviv District
Overview
Sarai Bronfeld is a Partner at NFX, with a background in business operations and investment roles. She has held key positions at companies like DreamTeam, 2130 Labs, and TytoCare, showcasing her expertise in business strategy and operations.
Bronfeld's career highlights include serving as a Board Member at DreamTeam and playing a crucial role as Head of Business Operations at 2130 Labs, demonstrating her leadership skills and ability to drive successful business operations.
Work Experience
Board Member
2024 - Current
Partner
2024
Principal
2022 - 2024
Associate
2021 - 2022
$450M pre-seed and seed only Venture Capital. SF\IL-based. ~$1B AUM.
NFX Bio is a fund initiative that seeks to invest in scientist-founders at the seed stage with a technology platform approach.
Board Member
2024
Judge\Mentor
2021
Business Consultant
2021 - 2024
Investor
2018 - 2021
Late-stage and pre IPOs. $100M AUM.
Head Of Business Operations
2019 - 2020
Business Operations
2019 - 2020
CSO
2018 - 2020
Research Scientist
2017 - 2019
Research focused on the endocrine and paracrine aspects of pancreatic cancer development and tumor metabolism. Master thesis on Klotho Gene, hormone that links longevity to cancer protection. Thesis Supervisor: Prof. Ido Wolf, Director of Oncology Department.